
CXCR 4‐mediated osteosarcoma growth and pulmonary metastasis is suppressed by Micro RNA ‐613
Author(s) -
Zhu Yong,
Tang Lanhua,
Zhao Shushan,
Sun Buhua,
Cheng Liang,
Tang Yifu,
Luo Zhongwei,
Lin Zhangyuan,
Zhu Jianxi,
Zhu Weihong,
Zhao Ruibo,
Lu Bangbao,
Long Haitao
Publication year - 2018
Publication title -
cancer science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 1347-9032
DOI - 10.1111/cas.13653
Subject(s) - osteosarcoma , cancer research , stromal cell , metastasis , cell growth , transforming growth factor , biology , medicine , cancer , genetics
Osteosarcoma is the most common primary bone malignancy. Recently, studies showed chemokine receptor 4 ( CXCR 4) played a critical role in osteosarcoma. However, the regulation of CXCR 4 is not fully understood. micro RNA s are short, non‐coding RNA s that play an important roles in post‐transcriptional regulation of gene expression in a variety of diseases including osteosarcoma. miR‐613 is a newly discovered mi RNA and has been reported to function as a tumor suppressor in many cancers. In this study, we confirmed that both Stromal Cell‐Derived Factor ( SDF ‐1) and CXCR 4 could be prognostic markers for osteosarcoma. Meanwhile this study found that SDF ‐1/ CXCR 4 pathway regulated osteosarcoma cells proliferation, migration and reduced apoptosis. Besides, we demonstrated that miR‐613 was significantly downregulated in osteosarcoma patients. Elevated expression of miR‐613 directly suppressed CXCR 4 expression and then decreased the proliferation, migration and induced apoptosis of osteosarcoma cells. Moreover, our study found that CXCR 4 promoted the development of lung metastases and inhibition of CXCR 4 by miR‐613 reduced lung metastases. These data indicated that CXCR 4 mediated osteosarcoma cell growth and lung metastases and this effect can be suppressed by miR‐613 through directly downregulating CXCR 4.